Analysts Set $8.88 Price Target for ADMA Biologics Inc (ADMA)
Shares of ADMA Biologics Inc (NASDAQ:ADMA) have earned a consensus broker rating score of 1.33 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and two have issued a strong buy rating on the company. ADMA Biologics’ rating score has improved by 20.4% from three months ago as a result of various analysts’ upgrades and downgrades.
Analysts have set a 12-month consensus target price of $8.88 for the company and are forecasting that the company will post ($0.51) earnings per share for the current quarter, according to Zacks. Zacks has also assigned ADMA Biologics an industry rank of 111 out of 265 based on the ratings given to its competitors.
ADMA has been the topic of several research reports. ValuEngine downgraded shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Raymond James Financial, Inc. raised shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research note on Tuesday, November 14th.
A hedge fund recently raised its stake in ADMA Biologics stock. Iguana Healthcare Management LLC raised its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 565,000 shares of the biotechnology company’s stock after buying an additional 415,000 shares during the quarter. Iguana Healthcare Management LLC owned about 2.19% of ADMA Biologics worth $1,740,000 at the end of the most recent quarter. Institutional investors own 33.18% of the company’s stock.
ADMA Biologics (NASDAQ:ADMA) opened at $2.87 on Tuesday. ADMA Biologics has a one year low of $2.01 and a one year high of $6.10. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26.
ADMA Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.